scholarly journals Data on the in vitro elution of substances from three types of polysulfone membrane dialyzers as well as a non-polysulfone cellulose triacetate membrane dialyzer evaluated using ultraviolet absorption

Data in Brief ◽  
2021 ◽  
pp. 107490
Author(s):  
Yoshinori Sato ◽  
Hayato Horiuchi ◽  
Shinji Fukasawa ◽  
Shingo Takesawa ◽  
Jun Hirayama
1998 ◽  
Vol 39 (4) ◽  
pp. 372-374 ◽  
Author(s):  
K. J. Berg ◽  
B. Rolfsen ◽  
G. Stake

Purpose, Material and Methods, and Results: The dialyzability of the high-molecular X-ray contrast medium iodixanol was examined in an in vitro hemo-dialysis model using two different hollow fiber membranes: one high-flux (polysulfone) membrane and one intermediate-flux (cellulose triacetate) membrane. Blood flow was 200 ml/min and membrane area 1.3 m2. The dialyzer clearance of iodixanol dissolved in a mixture of leukocyte-filtered SAG-M blood and compatible citrate plasma was 134.2±3.6 ml/min for the polysulfone membrane and 113.0±3.6 ml/min for the cellulose triacetate membrane. Conclusion: Iodixanol is readily dialyzed through commercial high-flux membranes.


1960 ◽  
Vol XXXIII (III) ◽  
pp. 444-450 ◽  
Author(s):  
Maria de la Luz Suarez Soto ◽  
Jean Legault Démare

ABSTRACT Serum gonadotrophin (PMS) when added to the incubation medium of rat ovary slices increases the amount of Δ4-3-ketosteroids produced. This enhancement is proportional to the logarithm of dose. The ketosteroids were determined by their ultraviolet absorption; paper chromatography has shown that only androst-4-en-3,17-dione is present.


2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Zhang Chen ◽  
Yang Yun ◽  
Nai-quan Liu ◽  
Guang-yu Zhou ◽  
De-tian Li

Abstract Background and Aims With the continuous development and optimization of dialysis membrane materials, polysulfone (PS) as the third generation of dialysis membrane has replaced cellulose triacetate (CTA) and dominated the market because of its better biocompatibility. However, we found that the hypersensitivity to PS could be remitted by the application of CTA in clinical practice. Objective to compare the differences in toxin removal, hematological change and biocompatibility in maintenance hemodialysis (MHD) patients using CTA dialyzer and PS dialyzer. Method A total of 20 MHD patients treated in the Second Blood Purification Center of Shengjing Hospital from June 2017 to September 2017 were enrolled in this study. They were randomly divided into group CTA and group PS (n=10/each group). They were treated with regular hemodialysis of 4 hours/time and 3 times/week for one month. The clearances of creatinine (CR), blood urea nitrogen (BUN) and serum phosphorus (P), the changes of hemoglobin (Hb), platelet (PLT) and white blood cell (WBC), and the differences of C-reactive protein (CRP), IgE, complement 3 (C3), vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) were compared between group CTA and group PS. Results Age (t=-0.735, P=0.465), gender (c2 =2.410, P=0.120), dialysis age (t=0.336, P=0.738) and primary diseases (c2 =3.817, P=0.701) had no statistical differences between the two groups. Before the hemodialysis with CTA dialyzer and PS dialyzer, there were no statistical differences in all of the parameters between the two groups (P>0.05). After application of CTA dialyzer and PS dialyzer for one month, ①there were no statistical differences in CR, BUN and P, nor in the changes of the above indicators between the two groups (P>0.05); ② there was a statistical difference in Hb change between the two groups (t=-2.282, P=0.027), with better improvement of anemia in group CTA; ③ there was a statistical difference in PLT (t=2.947, P=0.005) between the two groups, with slighter change in group CTA than in group PS (t= 2.219, P=0.031); ④there were no statistical significances in WBC, VCAM-1, ICAM-1, IgE, CRP and C3 between the two groups (P>0.05). Conclusion ①There were no significant difference in the clearances of small molecule toxins between CTA dialyzer and PS dialyzer. ② CTA was better than PS in the improvement of anemia. ③ The effect on PLT was less in group CTA than in group PS. ④ There were no significant differences in biocompatibility between CTA dialyzer and PS dialyzer.


2005 ◽  
Vol 51 (7) ◽  
pp. 1177-1184 ◽  
Author(s):  
Dorthe B Corlin ◽  
Jette W Sen ◽  
Søren Ladefoged ◽  
Grethe Bjerregaard Lund ◽  
Mogens H Nissen ◽  
...  

Abstract Background: Patients on chronic hemodialysis are prone to develop amyloid deposits of misfolded β2-microglobulin (β2M) in osteoarticular tissues. β2M with various deletions/truncations and chemical modifications has been found together with structurally intact β2M in extracts of β2M amyloid fibrils. The state of the circulating population of β2M molecules has not been characterized previously with high-resolution methods. Methods: We used immunoaffinity–liquid chromatography–mass spectrometry analysis of serum samples to examine whether structurally modified β2M is generated in the circulation. In addition, we developed an immunoassay for the quantification of a cleaved β2M variant in biological fluids based on novel monoclonal antibodies and applied this assay to patient and control sera. Results: A specific alteration compatible with the generation of lysine-58–cleaved and truncated β2M (ΔK58-β2M) was found in the sera of many (20%–40%) dialysis patients but not in control sera or sera from patients with cerebral amyloidosis (Alzheimer disease). Applied to patient sera, specific immunoassays revealed that dialysis, as expected, significantly lowered the total β2M concentration, but the concentrations of ΔK58-β2M remained unchanged after dialysis. The results also show that patients dialyzed with less biocompatible membranes have higher serum concentrations of cleaved β2M (mean, 8.5, 1.8, and 0.7 mg/L in cuprophane membrane-dialyzed, polysulfone membrane-dialyzed, and control sera, respectively). Conclusions: This study for the first time demonstrates and assigns the structure of a specific β2M variant in sera from dialysis patients. Because this variant is conformationally unstable in vitro, it may be involved in in vivo amyloidogenesis.


2003 ◽  
Vol 21 (2) ◽  
pp. 176-182 ◽  
Author(s):  
Takahiro Kuragano ◽  
Tsutomu Kuno ◽  
Yoshiko Takahashi ◽  
Chii Yamamoto ◽  
Yuji Nagura ◽  
...  

2021 ◽  
Vol 28 ◽  
pp. 101140
Author(s):  
Yoshinori Sato ◽  
Hayato Horiuchi ◽  
Shinji Fukasawa ◽  
Shingo Takesawa ◽  
Jun Hirayama
Keyword(s):  

2003 ◽  
Vol 26 (10) ◽  
pp. 897-905 ◽  
Author(s):  
V. Bordoni ◽  
I. Bolgan ◽  
A. Brendolan ◽  
C. Crepaldi ◽  
F. Gastaldon ◽  
...  

2013 ◽  
Vol 16 (5) ◽  
pp. 657 ◽  
Author(s):  
Kahina Daheb ◽  
Jean-Philippe Lecours ◽  
Mark L. Lipman ◽  
Patrice Hildgen ◽  
Julie J. Roy

Purpose. In order to update our data on drug dialyzability using the high-permeability dialysis membranes, atenolol elimination by an in vitro dialysis model was compared to that observed in six patients during high-permeability hemodialysis (HD), and the predictive value of the model was evaluated. Methods. Atenolol clearance was evaluated in six patients undergoing chronic HD. They were considered as eligible candidates if they were between 18 and 80 years of age, had a body mass index between 19 and 30 kg/m2, underwent HD and were taking atenolol on a regular basis in oral tablet form for at least 1 month before the study started. Atenolol clearance was also evaluated in three in vitro dialysis sessions with high-permeability polysulfone membrane. Atenolol was dissolved in 6 L of Krebs-Henseleit buffer with bovine serum albumin. Dialysis parameters were set to mirror as much as possible the patients’ parameters (flow rate: 300 mL/min, dialyzate flow: 500 mL/min). After sample collection, drug concentrations were measured with high performance liquid chromatography. The comparison between in vivo and in vitro atenolol elimination kinetics was performed by drawing the curve fittings of concentrations vs. time on SigmaPlot 12, and adding a 95% prediction interval to each elimination curve fitting. Results. Mean dialysis clearance of atenolol in vitro and in vivo was 198 ± 4 and 235 ± 53 mL/min, respectively. Atenolol was significantly removed within the study time period in both in vitro and in vivo experiments. By the end of in vitro dialysis, atenolol remaining in the drug reservoir was less than 2% of initial arterial concentration. Conclusion. Our study has indicated that atenolol is almost entirely cleared during high-permeability hemodialysis. Furthermore, the in vitro prediction interval of the drug elimination curve fitting could forecast its in vivo elimination especially at the end of dialysis. This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.


1960 ◽  
Vol 38 (11) ◽  
pp. 1255-1263 ◽  
Author(s):  
D. K. Myers

In extension of previous in vivo experiments, the effects of X irradiation on DPN were studied in vitro. No correlation between the effects on the ultraviolet absorption spectrum and on the coenzyme function of DPN was evident after irradiation at different pH values. However, the loss of coenzyme function could be correlated with the destruction of ribose and of riboside linkages. Catalase did not provide greater protection than did other proteins. It was concluded that the observed loss of DPN from irradiated cells is not due to the radiosensitivity of the DPN molecule itself.


Sign in / Sign up

Export Citation Format

Share Document